InDex Pharmaceuticals – Presentation of Q3 quarterly results
InDex Pharmaceuticals and CEO Peter Zerhouni present highlights from Q3 report and CMO Thomas Knittel deep dives into previous clinical results on cobitolimod.
InDex Pharmaceuticals AB is a development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate #cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals AB has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR / Corporate Visibility subscription agreement.